Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than other T cells, representing as little as 1% to 5% of the total CD3+ T ...

New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer. Has some of the early excitement in the cell ...

Despite their minority status within the T cell community, gamma-delta T cells are increasingly recognized for their dual ...

FLORIDA: The significance of gamma-delta T cells in 33 different cancer types is revealed in a recent study that was ...

GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies based on its Vδ1+ γδ T cell platforms for the treatment of solid tumors and beyond. Gamma delta (γδ) T ...

Join the 3rd Gamma Delta T Therapies Summit to learn and network ... globally accessible cell therapy for solid tumors. Enhance cytotoxicity, discover novel targets, engineer stealth, and ...

GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.

(Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...